Ali Behbahani Black Diamond Therapeutics, Inc. (BDTX) insider trading activity

BDTX Quotes by TradingView

Ali Behbahani is of Black Diamond Therapeutics, Inc.. Currently has a direct ownership of 57,584 shares of BDTX, which is worth approximately $139,353. The most recent transaction as insider was on Sep 20, 2024, when has been sold 3,007 shares (Common Stock) at a price of $4.78 per share, resulting in proceeds of $14,373. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 57.6K
5.51% 3M change
30.67% 12M change
Total Value Held $139,353

Ali Behbahani Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 20 2024
BUY
Grant, award, or other acquisition
$14,373 $4.78 p/Share
3,007 Added 4.96%
57,584 Common Stock
Jun 21 2024
BUY
Grant, award, or other acquisition
$14,377 $4.98 p/Share
2,887 Added 5.02%
54,577 Common Stock
Mar 15 2024
BUY
Grant, award, or other acquisition
$14,373 $4.54 p/Share
3,166 Added 5.77%
51,690 Common Stock
Dec 15 2023
BUY
Grant, award, or other acquisition
$12,162 $2.73 p/Share
4,455 Added 8.41%
48,524 Common Stock
Sep 15 2023
BUY
Grant, award, or other acquisition
$11,876 $3.6 p/Share
3,299 Added 6.96%
44,069 Common Stock
Jun 16 2023
BUY
Grant, award, or other acquisition
$11,875 $2.1 p/Share
5,655 Added 12.18%
40,770 Common Stock
Mar 16 2023
BUY
Grant, award, or other acquisition
$11,875 $1.67 p/Share
7,111 Added 16.84%
35,115 Common Stock
Dec 16 2022
BUY
Grant, award, or other acquisition
$11,875 $1.5 p/Share
7,917 Added 22.04%
28,004 Common Stock
Sep 16 2022
BUY
Grant, award, or other acquisition
$11,874 $2.62 p/Share
4,532 Added 18.41%
20,087 Common Stock
Jun 17 2022
BUY
Grant, award, or other acquisition
$11,875 $2.03 p/Share
5,850 Added 27.33%
15,555 Common Stock
Mar 18 2022
BUY
Grant, award, or other acquisition
$13,125 $3.02 p/Share
4,346 Added 30.93%
9,705 Common Stock
Dec 17 2021
BUY
Grant, award, or other acquisition
$13,126 $5.31 p/Share
2,472 Added 31.57%
5,359 Common Stock
Sep 17 2021
BUY
Grant, award, or other acquisition
$13,127 $9.9 p/Share
1,326 Added 31.47%
2,887 Common Stock
Jun 18 2021
BUY
Grant, award, or other acquisition
$13,131 $12.95 p/Share
1,014 Added 39.38%
1,561 Common Stock
Mar 18 2021
BUY
Grant, award, or other acquisition
$13,133 $24.01 p/Share
547 Added 50.0%
547 Common Stock

Also insider at

CRSP
CRISPR Therapeutics AG Healthcare
RGLS
Regulus Therapeutics Inc. Healthcare
> 10% Shareholder
MRKR
Marker Therapeutics, Inc. Healthcare
> 10% Shareholder
OYST
Oyster Point Pharma, Inc. Healthcare
Director
NKTX
Nkarta, Inc. Healthcare
GLUE
Monte Rosa Therapeutics, Inc. Healthcare
BHG
Bright Health Group Inc. Healthcare
CVRX
CVRx, Inc. Healthcare
ADAP
Adaptimmune Therapeutics PLC Healthcare
GNCA
GENOCEA BIOSCIENCES, INC. Healthcare
Director
TRVI
Trevi Therapeutics, Inc. Healthcare
> 10% Shareholder
UTRS
MINERVA SURGICAL INC Healthcare
Director
MTCR
Metacrine, Inc. Healthcare
> 10% Shareholder
AKUS
Akouos, Inc. Healthcare
> 10% Shareholder
ACLX
Arcellx, Inc. Healthcare
MIRM
Mirum Pharmaceuticals, Inc. Healthcare
> 10% Shareholder
SVRA
Savara Inc Healthcare
> 10% Shareholder
FREQ
Frequency Therapeutics, Inc. Healthcare
MBX
MBX Biosciences, Inc.
AB

Ali Behbahani

Timonium, MD

Track Institutional and Insider Activities on BDTX

Follow Black Diamond Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BDTX shares.

Notify only if

Insider Trading

Get notified when an Black Diamond Therapeutics, Inc. insider buys or sells BDTX shares.

Notify only if

News

Receive news related to Black Diamond Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on BDTX